Skip to main content
Premium Trial:

Request an Annual Quote

US Food and Drug Administration, SuperArray Bioscience

Premium

The US Food and Drug Administration has granted 510(k) clearance for BD Diagnostics’ ProbeTec ET Legionella pneumophila assay, the company said last week.

The test, based on BD’s real-time nucleic acid-amplification technology called Strand Displacement Amplification, is designed to detect L. pneumophila serogroups 1 - 14 in one hour. The bacterium causes Legionnaire’s disease. BD said it is “one of several” assays under development at the company designed to detect organisms responsible for atypical pneumonia. Other assays for this indication include the Chlamydiaceae family and Mycoplasma pneumoniae, BD said.


SuperArray Bioscience has launched its real-time gene-expression assay kits for “every gene” in the human, mouse, and rat genomes, the company said last week.

These quantitative gene-expression assays are intended for genome-wide disease characterization, pathway elucidation, functional studies, and in the basic research of human disease.

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.